Last reviewed · How we verify
Investigational varicella vaccine_Lot 1
Investigational varicella vaccine_Lot 1 is a Live attenuated vaccine or inactivated vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of varicella (chickenpox) in pediatric and/or adult populations.
This investigational vaccine stimulates the immune system to recognize and prevent varicella-zoster virus infection by inducing protective antibodies and cell-mediated immunity.
This investigational vaccine stimulates the immune system to recognize and prevent varicella-zoster virus infection by inducing protective antibodies and cell-mediated immunity. Used for Prevention of varicella (chickenpox) in pediatric and/or adult populations.
At a glance
| Generic name | Investigational varicella vaccine_Lot 1 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Live attenuated vaccine or inactivated vaccine |
| Target | Varicella-zoster virus (VZV) antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Varicella vaccines work by introducing attenuated or inactivated varicella-zoster virus antigen to prime both humoral and cellular immune responses. This allows the body to mount a rapid and effective immune response upon exposure to wild-type virus, preventing primary infection (chickenpox) or reducing disease severity. The vaccine trains memory B and T cells to recognize viral epitopes.
Approved indications
- Prevention of varicella (chickenpox) in pediatric and/or adult populations
Common side effects
- Injection site erythema or swelling
- Fever
- Rash
- Myalgia or arthralgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational varicella vaccine_Lot 1 CI brief — competitive landscape report
- Investigational varicella vaccine_Lot 1 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Investigational varicella vaccine_Lot 1
What is Investigational varicella vaccine_Lot 1?
How does Investigational varicella vaccine_Lot 1 work?
What is Investigational varicella vaccine_Lot 1 used for?
Who makes Investigational varicella vaccine_Lot 1?
What drug class is Investigational varicella vaccine_Lot 1 in?
What development phase is Investigational varicella vaccine_Lot 1 in?
What are the side effects of Investigational varicella vaccine_Lot 1?
What does Investigational varicella vaccine_Lot 1 target?
Related
- Drug class: All Live attenuated vaccine or inactivated vaccine drugs
- Target: All drugs targeting Varicella-zoster virus (VZV) antigens
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of varicella (chickenpox) in pediatric and/or adult populations
- Compare: Investigational varicella vaccine_Lot 1 vs similar drugs
- Pricing: Investigational varicella vaccine_Lot 1 cost, discount & access